General Information


  • IM deep injection into large muscle mass
  • IV push over 3-5 minutes
  • Intermittent infusion over 30 minutes (preferred) -Consider ordering PICC line for long term administration due to IV site adverse effects

Preparation IM

  • reconstitute vial with SWFI, bacteriostatic water, lidocaine 0.5% or 1%
  • 500mg vials reconstituted with 1.5mL, 1g vials with 3mL for final concentration of 280mg/mL Intravenous
  • 500mg vial reconstituted with 5.3mL SWFI giving concentration 100mg/mL
  • 1g and 2g vial with 10mL SWFI, final concentration varies (see manufacturer packaging)
  • 6g vial reconstituted with 26mL SWFI (concentration 200mg/mL) or 56mL SWFI (concentration 100mg/mL)


  • D5W, LR, NS

Broad gram negative coverage including Pseudomonas, generally used for nosocomial infections including post-neurosurgical meningitis, or other infections based on susceptibilities.

Notable lack of gram positive activity versus other cephalosporins.

Tier 2 Protected Antimicrobial

  • Broad spectrum, but 1st line for common infections, comes with a high risk of poor stewardship if initial workup and follow-up are not in place

Strategies Used:

  1. Appropriate workup initially
  2. Pharmacists audit/de-escalate
  3. Set EBM Duration
  • Renal function (nephrotoxicity)
  • neurotoxicity
  • PT/INR for patient at risk of elevations

Allergy (immediate and delayed).

  • Note potential cross-reactivity with aztreonam based on side chain.

Pruritis, skin rash, IV site reactions

Positive Coombs, eosinophilia

Increased hepatic enzymes

  • Chloramphenicol: diminish therapeutic effect of Ceftazidime
  • Aminoglycosides: enhance nephrotoxic effects of AGs
  • Probenecid: increase concentration of cephalosporins
  • Vitamin K Antagonists: enhance anticoagulant effect of warfarin

Antimicrobial class: 3rd generation Cephalosporin

Pregnancy category: B

Average serum half life: 2 hours

  • Pre-term neonates: PNA 3 days half-life 8.7 hours, PNA 10 days half-life 5 hours

Urine penetration: Therapeutic, 80-90% of drug excreted unchanged into urine

Lung penetration: Therapeutic

CSF penetration: Therapeutic, higher concentration when meninges are inflamed

Biliary penetration: Moderate

Bone penetration: Therapeutic

Fortaz, Tazicef